Epigenetic clocks point to a short list of interventions linked with slower biological aging
Aging cannot be stopped, but a large analysis of blood-based epigenetic biomarkers suggests that some familiar interventions may move biological age in a more favorable direction. Diet quality, regular physical activity, and selected prescription drugs were associated with slower epigenetic aging, while over-the-counter supplements showed little convincing signal.
The central measure in this work was not chronological age, but biological age as read through DNA methylation patterns. Epigenetic clocks estimate how quickly the body is aging by tracking methyl groups attached to DNA, a system that changes over time and appears sensitive to stress, inflammation, metabolism, and disease burden. In practical terms, these biomarkers offer a way to detect shifts over months or years rather than waiting decades for endpoints such as disability, dementia, cardiovascular events, or death.
The analysis pooled data from 51 longitudinal intervention studies and applied the same panel of 16 epigenetic clocks plus 94 additional DNA methylation biomarkers. That scale matters because aging studies often use different assays, different follow-up periods, and different patient groups, making comparisons difficult. By harmonizing the biomarker readouts, the investigators created a more consistent view of how interventions may influence biological aging signals across a broad range of studies.
One sentence captures the result plainly: diet, exercise, and some drugs changed the aging biomarkers; supplements did not.
Diet and exercise produced the most consistent biomarker shifts
Two lifestyle interventions stood out across the biomarker panel: eating a healthy diet and exercising regularly. The dietary patterns linked to slower epigenetic aging included Mediterranean, low-carbohydrate, and low-fat approaches. Exercise also showed a favorable association, reinforcing a long-standing clinical message that routine movement influences more than weight alone.
Biologically, these interventions are plausible because they act on systems that feed into aging itself. Better diet quality and physical activity improve insulin sensitivity, reduce visceral adiposity, and dampen chronic inflammatory tone. Those changes can alter methylation signatures tied to metabolic stress and cardiovascular risk, which helps explain why the biomarker readouts moved in a slower-aging direction.
The response pattern was not identical across every clock. Some biomarkers appeared more sensitive than others, and newer markers designed to estimate mortality risk or pace of aging seemed more responsive than clocks built mainly to estimate chronological age. In that sense, the choice of biomarker is not a technical footnote. It can determine whether a trial appears to show an effect at all.
Metformin, semaglutide, and anti-TNF therapy showed the largest drug effects
Among medications, metformin, semaglutide, and anti-TNF therapies were associated with reductions in epigenetic age across all 16 clocks studied. These were the strongest pharmacologic signals in the analysis.
The biological logic is straightforward. Metformin alters glucose handling and may reduce metabolic stress. Semaglutide, a GLP-1 agonist used for type 2 diabetes and weight control, can improve weight-related metabolic strain and downstream inflammatory signaling. Anti-TNF therapies suppress inflammation directly, and chronic inflammation is one of the most plausible drivers of accelerated biological aging. When systemic inflammation falls, methylation patterns tied to immune activation and tissue stress may shift in a younger direction.
The size of the drug effect should not be misread as proof of anti-aging treatment. Many of the studies involved people with diabetes, obesity, or inflammatory disease, so the biomarker changes may partly reflect better control of the underlying illness rather than a direct reversal of aging. In other words, treating disease can make aging biomarkers look better because disease itself pushes those biomarkers in the wrong direction.
Supplements offered little evidence of meaningful anti-aging benefit
The supplement findings were far less compelling. Evidence for over-the-counter products was limited and inconsistent, with no strong indication that they improved the epigenetic aging markers in a reliable way.
That does not mean supplements have no role in medicine. They can be important for documented deficiencies or specific clinical needs. But for generally healthy adults, the data in this analysis do not support the idea that pills marketed for longevity are likely to move aging biology in a measurable way. The gap between marketing claims and biomarker evidence remains wide.
The contrast is clinically relevant because it separates interventions with broad physiologic effects from those with speculative appeal. Diet, exercise, and disease treatment affect core pathways tied to metabolism and inflammation. Supplements often promise similar results without the same mechanistic reach.
Biomarker change is not the same as longer healthspan
The biggest caution in the study is also the most important one: a change in an epigenetic clock does not prove that aging has slowed in a way that will matter to patients. Biomarkers can be useful early signals, but they are still surrogates.
Raghav Sehgal, PhD, said the work shows whether these measures detect change, not whether the changes translate into people remaining healthier, functioning better, or living longer. That distinction is essential. A biomarker can move in the right direction while the clinical outcomes remain unchanged, and aging research has been burned by that gap before.
The next step is not simply to collect more clock measurements. It is to determine whether shifts in these biomarkers reliably predict preserved physical function, cognitive function, fewer chronic diseases, and longer healthspan. Until that link is established, epigenetic clocks should remain research tools rather than definitive clinical targets.
The bedside message still favors ordinary preventive care
The study does not produce a miracle intervention, and it does not change the basic prescription for healthy aging. Not smoking, exercising regularly, eating well, sleeping adequately, and managing blood pressure, cholesterol, and diabetes remain the most evidence-based measures available.
Sebnem Unluisler emphasized that regular aerobic and resistance exercise, a balanced Mediterranean-style diet, maintaining a healthy weight, limiting alcohol, and getting consistent sleep support long-term metabolic, cardiovascular, and cognitive health. Those habits are unglamorous, but they address the biology that matters most in routine practice.
A practical takeaway emerges from the data: the interventions most likely to influence aging biomarkers are the same ones clinicians already recommend for prevention. The medications with the largest biomarker shifts were studied in people with existing disease, so using them in healthy adults purely for longevity would outpace the evidence.
Aging biology may be measurable before it is modifiable in any definitive sense. For now, the strongest data still favor prevention, disease control, and behavior change over supplements or unproven anti-aging products.